Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-011 (pidilizumab) in DLBCL post-ASCT
NCT00532259Phase 2Completed
- Sponsor
- CureTech
- Start
- Oct 2007
- Primary completion
- Aug 2011
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of pidilizumab in diffuse large B-cell lymphoma (DLBCL), sponsored by CureTech. Primary endpoint: Progression-free Survival at 16 months. Started Oct 2007; status: completed.
02
Drugs
pidilizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00532259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00532259.